MYGN
Myriad Genetics, Inc.
Halal Rating :
Last Price
$12.38
Last updated:
Market Cap
-
7D Change
-13.34%
1 Year Change
-42.06%
Company Overview
Industries
Exchange
Next Earnings Date
Myriad Genetics, Inc. is a molecular diagnostic company that develops and markets predictive, personalized, and prognostic medicine tests. They specialize in analyzing human genes and their mutations to determine disease risk, assess the need for various medications, and guide treatment decisions primarily in the fields of oncology, women's health, and mental health.
Use of Interest
| Reporting Date | Total Revenue | Total Operating Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|---|---|---|---|---|---|
| Sept. 30, 2024 | $213.3m | $234.1m | - | $800000.0 | 0.00% | 0.34% |
| June 30, 2024 | $211.5m | $248.8m | - | $800000.0 | 0.00% | 0.32% |
| March 31, 2024 | $202.2m | $230.6m | - | $500000.0 | 0.00% | 0.22% |
Company Impact
Help us evaluate Myriad Genetics, Inc.'s impact from a halal perspective. Vote on the most significant aspect and submit any considerations that we may have missed.